|
Dr. Janet Hammond, Chief Medical Officer, will support marketed and development compounds in the Valeant portfolio such as Infergen®, Diastat® AcuDialTM, Zelapar®, Tasmar®, Cesamet®, retigabine and taribavirin. Her responsibilities include medical strategy, protocol development, post-marketing studies, communications and safety. Dr. Hammond is trained in Internal Medicine, Infectious Diseases and Critical Care Medicine, and comes to Valeant from Bristol-Myers Squibb where she was responsible for Anti-Infectives and HIV Global Clinical Development. Earlier in her career, she was a Senior Clinical Research Physician and Clinical Program Head in Clinical Development at GlaxoWellcome and subsequently head of Clinical Discovery for Antivirals in the Center for Excellence in Clinical Drug Discovery (CEDD) at GlaxoSmithKline. Her distinguished career includes an impressive list of accomplishments in clinical research, drug development, discovery research and post marketing support during her ten years in the pharmaceutical industry. She obtained her undergraduate medical training at the University of Cape Town, South Africa, and post-graduate training in Internal Medicine and Critical Care Medicine. She was admitted as a Fellow of the College of Physicians of South Africa and obtained her Ph.D. in epidemiology from the University of Cape Town. She trained in Infectious Diseases at Duke University, N.C. and Johns Hopkins University, Baltimore, MD, where she obtained a Masters in Clinical Investigation from the Johns Hopkins School of Hygiene and Public Health. | 